Overview

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with GanfortĀ® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or ocular hypertension.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol
Criteria
Inclusion Criteria:

- Patient has ocular hypertension or glaucoma in both eyes

- Requires IOP-lowering therapy in each eye

Exclusion Criteria:

- Active or recurrent eye disease that would interfere with interpretation of study data
in either eye

- History of any eye surgery or laser in either eye within 6 months

- Required chronic use of other eye medications during the study

- Anticipated wearing of contact lenses during the study.

- Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days